Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
By studying the roles of an inflammatory protein and antibodies in chronic rejection after lung transplantation, researchers discover possibilities for new treatments.
The lung stiffness and scarring characteristic of this rare disease may be linked to environmental gene alterations.
Under development at C.S. Mott Children’s Hospital, the pediatric artificial lung could offer new hope for treating children with lung failure.
Successfully tested in mice, targeted drug and gene therapies might one day benefit patients with a deadly lung disease, new U-M research finds.